The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

It has been alternatively called cranial arteritis or temporal arteritis, reflecting the most commonly affected vessels. However, this terminology minimizes the systemic nature of this vasculitis ...

Unlike PMR, temporal arteritis requires immediate medical attention. Delays in treatment might have major repercussions, such as blindness or stroke. As per the Arthritis Foundation, If you are ...

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib), 15 mg, once daily, ...

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...

GCA is an autoimmune disease that causes inflammation of the temporal and other cranial ... and potentially severe outcomes, such as blindness, aortic aneurysm, or stroke.

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with ...